Cardiopatia e diabete

dalla fisiopatologia alle soluzioni terapeutiche.

Translated title of the contribution: Heart disease and diabetes: from pathophysiology to therapeutic options

Gabriele Fragasso, Altin Palloshi, Giorgio Bassanelli, Robbert Steggerda, Chiara Montano, Alberto Margonato

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The incidence of diabetes mellitus is becoming progressively more frequent. The majority of diabetic patients will develop cardiovascular complications, among which coronary artery disease and diabetic cardiomyopathy are the most frequent and insidious. Apart from a meticulous metabolic control of diabetes, cardiac and vascular complications should be aggressively treated using the usual drugs at present effectively employed for their treatment in the general population. Additionally, the possibility of modifying cardiac substrate metabolism of the diabetic heart appears particularly attractive. Specifically, the possibility of increasing glucose metabolism rate and, accordingly, reducing free fatty acid oxidation, appears to be a very attractive therapeutic approach. Indeed, among traditional pharmacological tools, there is growing evidence that specific metabolically active drugs, the so-called partial free fatty acid inhibitors, of which the most studied is trimetazidine, will play an increasing role in the treatment of diabetic patients with coronary artery disease and cardiomyopathy. The property of these drugs is to facilitate myocardial utilization of glucose instead of free fatty acids which, in the context of ischemic and dysfunctional myocardial cells, appears to be deleterious. Similarly to other compounds that stimulate pyruvate dehydrogenase activity thereby facilitating glucose oxidation and inhibiting free fatty acid oxidation, such as dichloroacetate, trimetazidine has been shown to improve left ventricular function in diabetic patients with heart failure. Prospective studies in large clinical trials would produce more objective and definitive insights into the specific value of these new therapeutic concepts in the treatment of diabetic patients with cardiac diseases.

Original languageItalian
JournalItalian Heart Journal
Volume5 Suppl 2
Publication statusPublished - Mar 2004

Fingerprint

Heart Diseases
Nonesterified Fatty Acids
Trimetazidine
Glucose
Coronary Artery Disease
Diabetic Cardiomyopathies
Pharmaceutical Preparations
Therapeutics
Pyruvic Acid
Cardiomyopathies
Left Ventricular Function
Blood Vessels
Diabetes Mellitus
Oxidoreductases
Heart Failure
Clinical Trials
Prospective Studies
Pharmacology
Incidence
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiopatia e diabete : dalla fisiopatologia alle soluzioni terapeutiche. / Fragasso, Gabriele; Palloshi, Altin; Bassanelli, Giorgio; Steggerda, Robbert; Montano, Chiara; Margonato, Alberto.

In: Italian Heart Journal, Vol. 5 Suppl 2, 03.2004.

Research output: Contribution to journalArticle

Fragasso, G, Palloshi, A, Bassanelli, G, Steggerda, R, Montano, C & Margonato, A 2004, 'Cardiopatia e diabete: dalla fisiopatologia alle soluzioni terapeutiche.', Italian Heart Journal, vol. 5 Suppl 2.
Fragasso, Gabriele ; Palloshi, Altin ; Bassanelli, Giorgio ; Steggerda, Robbert ; Montano, Chiara ; Margonato, Alberto. / Cardiopatia e diabete : dalla fisiopatologia alle soluzioni terapeutiche. In: Italian Heart Journal. 2004 ; Vol. 5 Suppl 2.
@article{ca342582517c48adab72d7f5349fe5ca,
title = "Cardiopatia e diabete: dalla fisiopatologia alle soluzioni terapeutiche.",
abstract = "The incidence of diabetes mellitus is becoming progressively more frequent. The majority of diabetic patients will develop cardiovascular complications, among which coronary artery disease and diabetic cardiomyopathy are the most frequent and insidious. Apart from a meticulous metabolic control of diabetes, cardiac and vascular complications should be aggressively treated using the usual drugs at present effectively employed for their treatment in the general population. Additionally, the possibility of modifying cardiac substrate metabolism of the diabetic heart appears particularly attractive. Specifically, the possibility of increasing glucose metabolism rate and, accordingly, reducing free fatty acid oxidation, appears to be a very attractive therapeutic approach. Indeed, among traditional pharmacological tools, there is growing evidence that specific metabolically active drugs, the so-called partial free fatty acid inhibitors, of which the most studied is trimetazidine, will play an increasing role in the treatment of diabetic patients with coronary artery disease and cardiomyopathy. The property of these drugs is to facilitate myocardial utilization of glucose instead of free fatty acids which, in the context of ischemic and dysfunctional myocardial cells, appears to be deleterious. Similarly to other compounds that stimulate pyruvate dehydrogenase activity thereby facilitating glucose oxidation and inhibiting free fatty acid oxidation, such as dichloroacetate, trimetazidine has been shown to improve left ventricular function in diabetic patients with heart failure. Prospective studies in large clinical trials would produce more objective and definitive insights into the specific value of these new therapeutic concepts in the treatment of diabetic patients with cardiac diseases.",
author = "Gabriele Fragasso and Altin Palloshi and Giorgio Bassanelli and Robbert Steggerda and Chiara Montano and Alberto Margonato",
year = "2004",
month = "3",
language = "Italian",
volume = "5 Suppl 2",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",

}

TY - JOUR

T1 - Cardiopatia e diabete

T2 - dalla fisiopatologia alle soluzioni terapeutiche.

AU - Fragasso, Gabriele

AU - Palloshi, Altin

AU - Bassanelli, Giorgio

AU - Steggerda, Robbert

AU - Montano, Chiara

AU - Margonato, Alberto

PY - 2004/3

Y1 - 2004/3

N2 - The incidence of diabetes mellitus is becoming progressively more frequent. The majority of diabetic patients will develop cardiovascular complications, among which coronary artery disease and diabetic cardiomyopathy are the most frequent and insidious. Apart from a meticulous metabolic control of diabetes, cardiac and vascular complications should be aggressively treated using the usual drugs at present effectively employed for their treatment in the general population. Additionally, the possibility of modifying cardiac substrate metabolism of the diabetic heart appears particularly attractive. Specifically, the possibility of increasing glucose metabolism rate and, accordingly, reducing free fatty acid oxidation, appears to be a very attractive therapeutic approach. Indeed, among traditional pharmacological tools, there is growing evidence that specific metabolically active drugs, the so-called partial free fatty acid inhibitors, of which the most studied is trimetazidine, will play an increasing role in the treatment of diabetic patients with coronary artery disease and cardiomyopathy. The property of these drugs is to facilitate myocardial utilization of glucose instead of free fatty acids which, in the context of ischemic and dysfunctional myocardial cells, appears to be deleterious. Similarly to other compounds that stimulate pyruvate dehydrogenase activity thereby facilitating glucose oxidation and inhibiting free fatty acid oxidation, such as dichloroacetate, trimetazidine has been shown to improve left ventricular function in diabetic patients with heart failure. Prospective studies in large clinical trials would produce more objective and definitive insights into the specific value of these new therapeutic concepts in the treatment of diabetic patients with cardiac diseases.

AB - The incidence of diabetes mellitus is becoming progressively more frequent. The majority of diabetic patients will develop cardiovascular complications, among which coronary artery disease and diabetic cardiomyopathy are the most frequent and insidious. Apart from a meticulous metabolic control of diabetes, cardiac and vascular complications should be aggressively treated using the usual drugs at present effectively employed for their treatment in the general population. Additionally, the possibility of modifying cardiac substrate metabolism of the diabetic heart appears particularly attractive. Specifically, the possibility of increasing glucose metabolism rate and, accordingly, reducing free fatty acid oxidation, appears to be a very attractive therapeutic approach. Indeed, among traditional pharmacological tools, there is growing evidence that specific metabolically active drugs, the so-called partial free fatty acid inhibitors, of which the most studied is trimetazidine, will play an increasing role in the treatment of diabetic patients with coronary artery disease and cardiomyopathy. The property of these drugs is to facilitate myocardial utilization of glucose instead of free fatty acids which, in the context of ischemic and dysfunctional myocardial cells, appears to be deleterious. Similarly to other compounds that stimulate pyruvate dehydrogenase activity thereby facilitating glucose oxidation and inhibiting free fatty acid oxidation, such as dichloroacetate, trimetazidine has been shown to improve left ventricular function in diabetic patients with heart failure. Prospective studies in large clinical trials would produce more objective and definitive insights into the specific value of these new therapeutic concepts in the treatment of diabetic patients with cardiac diseases.

UR - http://www.scopus.com/inward/record.url?scp=16644391077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644391077&partnerID=8YFLogxK

M3 - Articolo

VL - 5 Suppl 2

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

ER -